NEOS News and Press, Neos Therapeutics Inc. From 03/13/20

Neos Therapeutics (NASDAQ: NEOS ): Q4 GAAP EPS of -$0.07 misses by $0.04 . More news on: Neos Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

– Full year 2019 net revenues increased by 29% and operating loss decreased by $33M – –  Neos RxConnect rapidly expanded with ~500 pharmacies in network at year-end – – NT0502 Phase 1 ascending dose trial initiation planned in 2H20 following ...

DALLAS and FORT WORTH, Texas, March 06, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its fourth quarter and year-end 2019 f...

DALLAS and FORT WORTH, Texas, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Office...

NOTE: All tables, graphs, charts and inserts below were prepared by the author based on company filing's (unless otherwise noted). Our analysis concludes NEOS Therapeutics (ticker symbol "NEOS") share price is materially undervalued because: NEOS trades at much lower forward looking re...

DALLAS and FORT WORTH, Texas, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it has initiated and completed dosing in a Phase ...

Neos Therapeutics ( NEOS ) stock has been lingering despite progress on multiple fronts. The company's drugs have displayed impressive revenue growth and perhaps even more impressive is the reduced cost, which has put the company on a path to profitability. Here is an overview of their prod...

Since my first Neos Therapeutics ( NEOS ) article, the company has been executing on all fronts and continues to execute their concentrated commercial strategy. As a result, the company has recorded another encouraging quarter of progress toward achieving profitability. The company was abl...

Neos Therapeutics, Inc. (NASDAQ:NEOS) Q3 2019 Earnings Conference Call November 8, 2019 8:30 AM ET Company Participants Jerry McLaughlin - Chief Executive Officer Richard Eisenstadt - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Ken...

The following slide deck was published by Neos Therapeutics, Inc. in conjunction with their 2019 Q3 earnings Read more ...